

JUN 30 2003

Sub 2
B2
11. (AMENDED)

The antagonist of claim [8] 10 wherein said monoclonal antibody is a monoclonal antibody having the binding specificity of monoclonal antibody HU177, HUIV26 or XL313.

ENTER 1600/2900

B3
20. (AMENDED)

The method of claim [19] 60 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.

21. (AMENDED)

The method of claim [19] 60 wherein said antagonist is administered in conjunction with chemotherapy.

22. (AMENDED)

The method of claim [19] 60 wherein said antagonist is administered in conjunction with radiation.

23. (AMENDED)

The method of claim [19] 60 wherein the tissue is inflamed and angiogenesis is occurring.

B4
27. (AMENDED)

The method of claim [26] 61 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, topically or orally.

28. (AMENDED)

The method of claim [26] 61 wherein said antagonist is administered in conjunction with chemotherapy.

29. (AMENDED)

The method of claim [26] 61 wherein said antagonist is administered in conjunction with radiation.

30. (AMENDED)

The method of claim [26] 61 wherein the tumor or metastasis is a melanoma, carcinoma, sarcoma, fibrosarcoma, glioma or astrocytoma.

B5
32. (AMENDED)

The method of claim [31] 62 wherein said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.

33. (AMENDED) The method of claim [31] 62 wherein administering the antagonist is in conjunction with chemotherapy.

34. (AMENDED) The method of claim [31] 62 wherein administering the antagonist is in conjunction with radiation.

36. (AMENDED) The method of claim [35] 63 wherein said tissue is *ex vivo*.

37. (AMENDED) The method of claim [35] 63 wherein said tissue is *in vivo* and said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.

38. (AMENDED) The method of claim [35] 63 wherein said antagonist is conjugated to a fluorochrome, radioactive tag, paramagnetic heavy metal, diagnostic dye or enzyme.

40. (AMENDED) The method of claim [39] 64 wherein said tissue is *ex vivo*.

41. (AMENDED) The method of claim [39] 64 wherein said tissue is *in vivo* and said antagonist is administered intravenously, transdermally, intrasynovially, intramuscularly, intratumorally, intraocularly, intranasally, intrathecally, topically or orally.

42. (AMENDED) The method of claims [39] 64 wherein said antagonist is conjugated to a fluorochrome, radioactive tag, paramagnetic heavy metal or diagnostic dye.

43. (AMENDED) A method for screening for denatured collagen antagonists comprising:

- a) providing a putative antagonist;
- b) measuring said putative antagonist's first affinity for a denatured collagen selected from the group consisting of collagens types I, II, III, IV and V;
- c) measuring said putative antagonist's second affinity for a native collagen selected from the group consisting of collagens types I, II, III, IV and V, wherein said native collagen selected is the native form of the denatured collagen selected; and

57
d) selecting said putative antagonist as a denatured collagen antagonist if said second affinity is substantially less than said first affinity.

58
56. (AMENDED) [An] A peptide comprising a sequence encoding an epitope recognized by [an] the antagonist of claim 1.

NEW CLAIMS

Please ADD the following new claims:

60. A method of inhibiting angiogenesis in a tissue comprising administering the antagonist of claim 1.

61. A method of inhibiting tumor growth or metastasis in a tissue comprising administering the antagonist of claim 1.

62. A method of inhibiting psoriasis, macular degeneration, or restenosis in a tissue comprising administering the antagonist of claim 1.

63. A method of detecting angiogenesis in a tissue comprising contacting the antagonist of claim 1 with said tissue.

64. A method of detecting tumors or tumor invasion in a tissue comprising administering the antagonist of claim 1.


These amendments and new claims are fully supported by the specification as filed.

Please address all correspondence regarding this communication to the following address:

Dated: June 13, 2000

Respectfully submitted,

McCutchen, Doyle, Brown & Enersen, LLP

By: 
RAJIV YADAV
Registration No.: 43,999

McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center
San Francisco, California 94111
Telephone: (415) 393-2000
Telefax: (415) 393-2286